目的探讨血清微小RNA(miRNA)-106a和miRNA-20a水平与新生儿呼吸窘迫综合征(NRDS)严重程度及预后的相关性。方法选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组,其中男77例,女79例,出生胎龄(33.87±...目的探讨血清微小RNA(miRNA)-106a和miRNA-20a水平与新生儿呼吸窘迫综合征(NRDS)严重程度及预后的相关性。方法选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组,其中男77例,女79例,出生胎龄(33.87±2.01)周。根据NRDS患儿胸部影像检查结果将其分为轻度组(50例)、中度组(74例)和重度组(32例)。根据NRDS患儿结局将其分为预后良好组132例和预后不良组24例。另选取同期在西安交通大学附属红会医院体检的健康早产儿150例作为对照组,其中男77例,女73例,出生胎龄(34.05±1.83)周。采用定量聚合酶链式反应(qPCR)测定血清miRNA-106a和miRNA-20a水平;采用Pearson相关分析NRDS患儿血清miRNA-106a和miRNA-20a水平与新生儿急性生理评分(SNAPPE-Ⅱ)、1 min Apgar评分的相关性;采用受试者操作特征曲线(ROC)评价血清miRNA-106a和miRNA-20a水平预测NRDS患儿预后的价值。采用t检验、χ^(2)检验。结果NRDS组患儿血清miRNA-106a和miRNA-20a水平低于对照组[(0.97±0.30)比(1.70±0.53)、(0.88±0.32)比(1.57±0.55)],差异均有统计学意义(t=14.750、13.346,均P<0.05)。重度组、中度组、轻度组血清miRNA-106a和miRNA-20a水平及1 min Apgar评分比较,差异均有统计学意义(均P<0.05)。预后不良组NRDS患儿血清miRNA-106a和miRNA-20a水平低于预后良好组[(0.40±0.19)比(1.07±0.36)、(0.39±0.17)比(0.97±0.34)],SNAPPE-Ⅱ评分高于预后良好组[(34.25±6.50)分比(18.10±3.58)分],差异均有统计学意义(t=13.438、12.718、11.850,均P<0.05)。血清miRNA-106a和miRNA-20a水平与SNAPPE-Ⅱ评分呈负相关(均P<0.05),与1 min Apgar评分呈正相关(均P<0.05)。miRNA-106a、miRNA-20a预测NRDS患儿预后不良的灵敏度分别为95.8%、91.7%,特异度分别为93.2%、89.4%,曲线下面积(AUC)分别为0.961(95%CI 0.929~0.992)、0.938(95%CI 0.900~0.976),表明这些生物标志物预测NRDS患儿预后准确度较高。miRNA-106a联合miRNA-20a的灵敏度和特异度分别为91.7%、97.7%,AUC为0.984(95%CI 0.967~1.000),表明联合检测具有更高的预测效能。结论血清miRNA-106a和miRNA-20a水平在NRDS患儿中降低,且其水平随NRDS患儿严重程度加重而逐渐降低,二者在预测NRDS患儿预后中具有重要价值。展开更多
Objective：Research has demonstrated that microRNA（miR）-106a is related to cisplatin resistance.We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer（NSCLC）and their s...Objective：Research has demonstrated that microRNA（miR）-106a is related to cisplatin resistance.We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer（NSCLC）and their sensitivity to chemotherapy by cisplatin combined with gemcitabine.Methods：Eighty-five NSCLC patients,who completed four cycles of gemcitabine and cisplatin chemotherapy,volunteered for this study and their serum samples were collected.Serum samples from 60 healthy subjects were used as controls.Real-time quantitative polymerase chain reaction（real-time q PCR）was used to quantify the level of miR-106a in the serum.Demographic and survival data of these patients were collected for the analysis.Results：The expression of miR-106a in the serum of NSCLC patients was significantly higher than that of healthy subjects（P＆lt;0.001）.The expression of miR-106a was not correlated with patients＇gender,age,tumor size,lymphatic metastasis,and pathological types;but was correlated with patients＇tumor staging（P=0.003）.After chemotherapy,serum miR-106a expression decreased in patients.The decrease in miR-106a expression in the chemotherapy-sensitive group was much higher than that in the chemotherapy-resistant group.Survival analysis shows that NSCLC patients with high expression of miR-106a have a poorer prognosis.The overall survival of NSCLC patients in the chemotherapy-sensitive group was significantly higher than that in the chemotherapy-resistant group.Conclusions：High expression of miR-106a may be involved in the development of NSCLC.Mi R-106a has significance in the prognosis of NSCLC.The level of miR-106a in the serum can be a useful parameter in screening for drug resistance during cisplatin-based chemotherapy.展开更多
文摘目的探讨血清微小RNA(miRNA)-106a和miRNA-20a水平与新生儿呼吸窘迫综合征(NRDS)严重程度及预后的相关性。方法选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组,其中男77例,女79例,出生胎龄(33.87±2.01)周。根据NRDS患儿胸部影像检查结果将其分为轻度组(50例)、中度组(74例)和重度组(32例)。根据NRDS患儿结局将其分为预后良好组132例和预后不良组24例。另选取同期在西安交通大学附属红会医院体检的健康早产儿150例作为对照组,其中男77例,女73例,出生胎龄(34.05±1.83)周。采用定量聚合酶链式反应(qPCR)测定血清miRNA-106a和miRNA-20a水平;采用Pearson相关分析NRDS患儿血清miRNA-106a和miRNA-20a水平与新生儿急性生理评分(SNAPPE-Ⅱ)、1 min Apgar评分的相关性;采用受试者操作特征曲线(ROC)评价血清miRNA-106a和miRNA-20a水平预测NRDS患儿预后的价值。采用t检验、χ^(2)检验。结果NRDS组患儿血清miRNA-106a和miRNA-20a水平低于对照组[(0.97±0.30)比(1.70±0.53)、(0.88±0.32)比(1.57±0.55)],差异均有统计学意义(t=14.750、13.346,均P<0.05)。重度组、中度组、轻度组血清miRNA-106a和miRNA-20a水平及1 min Apgar评分比较,差异均有统计学意义(均P<0.05)。预后不良组NRDS患儿血清miRNA-106a和miRNA-20a水平低于预后良好组[(0.40±0.19)比(1.07±0.36)、(0.39±0.17)比(0.97±0.34)],SNAPPE-Ⅱ评分高于预后良好组[(34.25±6.50)分比(18.10±3.58)分],差异均有统计学意义(t=13.438、12.718、11.850,均P<0.05)。血清miRNA-106a和miRNA-20a水平与SNAPPE-Ⅱ评分呈负相关(均P<0.05),与1 min Apgar评分呈正相关(均P<0.05)。miRNA-106a、miRNA-20a预测NRDS患儿预后不良的灵敏度分别为95.8%、91.7%,特异度分别为93.2%、89.4%,曲线下面积(AUC)分别为0.961(95%CI 0.929~0.992)、0.938(95%CI 0.900~0.976),表明这些生物标志物预测NRDS患儿预后准确度较高。miRNA-106a联合miRNA-20a的灵敏度和特异度分别为91.7%、97.7%,AUC为0.984(95%CI 0.967~1.000),表明联合检测具有更高的预测效能。结论血清miRNA-106a和miRNA-20a水平在NRDS患儿中降低,且其水平随NRDS患儿严重程度加重而逐渐降低,二者在预测NRDS患儿预后中具有重要价值。
文摘Objective：Research has demonstrated that microRNA（miR）-106a is related to cisplatin resistance.We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer（NSCLC）and their sensitivity to chemotherapy by cisplatin combined with gemcitabine.Methods：Eighty-five NSCLC patients,who completed four cycles of gemcitabine and cisplatin chemotherapy,volunteered for this study and their serum samples were collected.Serum samples from 60 healthy subjects were used as controls.Real-time quantitative polymerase chain reaction（real-time q PCR）was used to quantify the level of miR-106a in the serum.Demographic and survival data of these patients were collected for the analysis.Results：The expression of miR-106a in the serum of NSCLC patients was significantly higher than that of healthy subjects（P＆lt;0.001）.The expression of miR-106a was not correlated with patients＇gender,age,tumor size,lymphatic metastasis,and pathological types;but was correlated with patients＇tumor staging（P=0.003）.After chemotherapy,serum miR-106a expression decreased in patients.The decrease in miR-106a expression in the chemotherapy-sensitive group was much higher than that in the chemotherapy-resistant group.Survival analysis shows that NSCLC patients with high expression of miR-106a have a poorer prognosis.The overall survival of NSCLC patients in the chemotherapy-sensitive group was significantly higher than that in the chemotherapy-resistant group.Conclusions：High expression of miR-106a may be involved in the development of NSCLC.Mi R-106a has significance in the prognosis of NSCLC.The level of miR-106a in the serum can be a useful parameter in screening for drug resistance during cisplatin-based chemotherapy.
